Medical network - on January 4, 2016, the medical market is still in the continuation of the powerful aura "policy", reform pilot provinces and cities to increase, "two votes", medicine circulation field of management, the classification system propulsion, such as health insurance payment standard pilot policy profoundly affects the medical market.
The provinces in implementation
Provincial drug centralized purchasing plan in 2015, the state file 7 general office of the state council on perfecting hospital drug centralized purchasing work guidance of "classification of purchasing, hierarchical management, step-by-step implementation of" purchasing under the guidance of the principle, as the culmination of a health care reform developed, and gradually push forward. But looking back to the provincial drug in implementation, still a lot of blind spots.
This round of drug centralized purchasing, the provincial basic implementation of the no. 7 the subject of the "drug target price". From has been completed and ongoing shandong, shanxi, hubei, fujian, guangxi, sichuan and other provinces to bidding directory or hang a web directory limit rules, first of all take more a few bid, refer to the latest issue of the national minimum average rules to limit or the lowest price, low price.
2 it is clinical dosage for sourcing classification of bidding directory, competitive enterprise products, the technical standard, after screening the same competition within the group, only get a lower quote lowest quotation and time as the winning companies, highlights the principle of low price preference. Even as the clinical dosage of shandong to hang net price products, but also put forward to cities or counties such or hospitals association negotiation need to refer to historical low price and the actual transaction price.
Another big market trend that is a delegate with anhui, zhejiang, chongqing municipal association of medical institutions in the round of tender and bid at the provincial level or to hang the net on the basis of negotiation, for different varieties of grassroots medical or health insurance directory, put forward the prices by 15% ~ 15% of the bid rules, push back a large number of drug production enterprises directly.
Shanghai GPO and GPO sourcing model also source out the pilot project in shenzhen, guangdong province, just changed the concept of implicit contribution points, put the interests of enterprises to contribute to a consortium. More cruel is the lowest price in Beijing, zhejiang reference dynamic adjustment, as long as the products appear cheaper in other places, for whatever reason, be complaints, mandatory after a certain period of time to adjust to the lowest price, otherwise regarded as out, at the same time, also was assimilation of beijing-tianjin-hebei league.
"Sanming mode" of fujian province is the most vocal consortium secondary bargaining, payment of fees and the combination of "two votes" the lowest price to purchase, in fujian province, the "wulitou" bad comparison (different specifications offer poor comparison rules have yet to find out the theoretical basis) and the strong medicine rules to low the overlord of the tender hang off-line, further compression drug prices "moisture". "Sanming mode" by national level model for typical, requirements in the nationwide promotion, and quickly by the national 46 cities to study, in sanming price for price, practice the "sanming mode" alliance.
Same, all all point to a target of the drug centralized purchasing, reduce the price.
Let the market talk price reform
Really achieve the goal of price? Regardless of patents, exclusive varieties for the kind of negotiations, only said is still the focus of drug centralized purchasing of clinical dosage big competitive varieties. Most provinces in the centralized purchasing rules of bidding directory, the clinical usage of varieties, competitive enterprise adhere to the centralized purchasing by bidding, but in rules, implement the quality layered or bidding grouping, patent, the original research, science and technology progress prize, the first copy, through the international certification, provincial quality prize, etc can be used as a hierarchy of standard project be layered or grouping of barrier line, as the first and second level product difference with ordinary GMP enterprise stratification or grouping.
There is no doubt that the end result is the first or second level competition of little or no competition become the winner of the price, bidding has become the patron saint of this batch of varieties. As some of the province, the first level varieties, some varieties had not participated in the competition in the market, bidding record is few, but after the hierarchical classification opportunity comes along, without the price part of washing products at higher prices, immediately become popular. Province in the tender varieties group, won the provincial science and technology progress prize or award of products is also included in the special arrangement, bid and dosage forms for different segment group, lead to some enterprise has no obvious advantage in other provinces products immediately become retailing bargaining varieties.
Drug centralized purchasing as a pioneer of reform policy, what is its fundamental goal? The author thinks that: adjust the drugs price to a reasonable price, straighten out the medical institutions drug structure, rationally spending is to control health care costs should fulfill the obligations. Some have obvious after fully market competition, price transparency of generic drug, drug products, should no longer be as per bidding round horse. And "the original, imported banner of foreign investment, joint venture drugs has been set up separately in a quality level or within the group, make health insurance money. And drug product at a lower price, countries could adjust the structure of hospital drug use, protect drug regulation at a lower price, but some provinces pretended to ignore, continues to urge local or medical institutions joint negotiation price again.
Since the drug bid can not fully accept the purpose of the reasonable adjustment of drug prices, it is time grading diagnosis and treatment, health care health control cost measures such as pay standard output. Policy is to guide the market, price reform policy choice let the market to talk, we chose to pay the standard regulation.
Industry gossip, payment standard for the price leads to greater efforts. The author thinks that, the key to see what product price reduction. Reasonable drug price regulation in place is king, who in a disguised form of patent, the original research, science and technology progress prize by profitable products can pass the standard cut down the price is reasonable, market competition fully generic drug products at a reasonable price in the market competition, but low-cost medicine give policy protection to a reasonable chance of survival if the goals are met. |
